ArticleGland surgery2021
A population-based analysis of adenosquamous carcinoma of the salivary gland.
Article in Gland surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Facial Nerve Paralysis Revealing Adenosquamous Carcinoma of the Parotid Gland: A Case Report.Cureus · 2026Article
- A real-world evaluation of tislelizumab in patients with head and neck cancer.Translational cancer research · 2024Article
- Survival and risk factors of adenosquamous carcinoma in the oral and maxillofacial region: a population-based study.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenosquamous carcinoma (ASC) of the salivary gland is a rare malignancy, and the characteristics and prognosis of this disease remain unclear. This study aimed to assess the clinicopathological characteristics of this rare disease and further determine the potential prognostic factors that affect its outcome.
methodsData of patients with ASC of the salivary gland were extracted retrospectively from the Surveillance, Epidemiology, and End Results (SEER) database between 1973 and 2016. The clinicopathological characteristics of these patients were assessed, and prognostic factors were further determined using Cox regression analysis.
resultsA total of 106 patients with ASC of the salivary gland were identified. The mean age at diagnosis was 66.1±14.9 years, with a male-to-female ratio of 1.47. The parotid gland was the most common primary site (N=91; 85.8%). The 1-, 2-, and 5-year overall survival (OS) rates were 71.5%, 55.0%, 41.5%, respectively. The 1-, 2-, and 5-year disease-specific survival (DSS) rates were 80.8%, 72.2%, and 59.2%, respectively. The OS and DSS shortened with increasing tumor stage, regardless of the American Joint Committee on Cancer tumor-node-metastasis stage or SEER historic stage. Surgery was the main treatment option to improve survival, and post-operative radiotherapy could also prolong OS and DSS (both P<0.01). A multivariate Cox regression analysis demonstrated that distant metastases and the use of surgery or radiation were independent prognostic factors for a favorable OS among patients with ASC of the salivary gland, and early stage (T1/T2) and the use of surgery were independent prognostic factors for favorable DSS among the patients with ASC of the salivary gland.
conclusionsThis is the largest case series on ASC of the salivary gland. Advanced T stage, distant metastases, and the use of surgery and radiation were associated with OS or DSS of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.